CD19 and cancer: Following the failure of CD19 CART therapy, various non-CART treatment options, such as chemotherapy, radiotherapy, targeted drugs (polatuzumab-vedotin-based, immune checkpoint inhibitors, and bispecific antibodies), have been employed for further anti-cancer therapies (5–7, 10–12).